New Blood Test Catches 90% of Aggressive Prostate Cancer

Finding prostate cancer early enough to cure it just got a whole lot easier.

A new blood test called Stockholm3 is outperforming the standard prostate screening that's been used since the 1990s. In a study of over 12,000 men, the test caught 90% of aggressive prostate cancer cases while the traditional PSA test only detected 74%.

That 16-point difference could mean thousands of lives saved. When aggressive prostate cancer is caught while still contained in the prostate, the five-year survival rate is nearly 100%. Miss it early, and the odds drop dramatically.

Researchers at Sweden's Karolinska Institutet followed participants for two years. During that time, 443 men were diagnosed with aggressive prostate cancer. Stockholm3 missed significantly fewer dangerous cases than the PSA test.

Here's what makes this even better: the new test didn't increase false alarms. The number of men incorrectly flagged as high-risk stayed about the same, meaning fewer unnecessary biopsies and MRIs for healthy men.

"One of the major challenges in prostate cancer is being able to identify the cases that are truly dangerous," said researcher Thorgerdur Palsdottir. The current PSA test has well-documented problems, including missing aggressive cancers while over-diagnosing harmless ones.

The timing couldn't be better. Data shows that metastatic prostate cancer has actually risen over the past decade, suggesting current screening methods aren't catching the dangerous cases early enough.

The test works by estimating a man's risk of aggressive prostate cancer through a simple blood draw. A biopsy would still be needed to confirm any diagnosis, but far fewer men would need to go through that invasive procedure.

Why This Inspires

This breakthrough represents exactly what medical screening should be: finding the cancers that need treatment while they're still curable, without putting healthy men through unnecessary anxiety and procedures. It's a win on both sides.

The Stockholm3 test could transform how millions of men are screened for one of the most common cancers. Better detection means more men getting treatment when it works best, and fewer men enduring painful biopsies for cancers that were never a threat.

The company behind Stockholm3 plans to seek FDA approval for use in the United States, with studies already underway to generate the necessary evidence. Early detection saves lives, and this test could become the new standard for doing exactly that.